Tagged with Association,

India Kanchana TK, director general of the Organisation of Pharmaceutical Producers of India (OPPI), the association which represents the interests of research-based pharmaceutical companies in India, discusses regulatory reform and how OPPI is helping to shape the Indian healthcare system. Please introduce yourself to our international readers and your journey to…

Canada Colette Rivet, executive director of the Cannabis Canada Association, leading Canadian licensed medical cannabis producers, talks regulatory challenges, upcoming opportunities, export ambitions and collaboration with the provincial and federal government in light of the upcoming legalization of cannabis for adult use in Canada. Colette, can you introduce the Cannabis Canada…

Japan Osamu Nagayama, president of the Japan BioIndustry Association (JBA) and chairman and CEO of Chugai Pharmaceutical, discusses Japan’s footprint in biologics and how mergers between Japanese pharma companies, thereby creating larger R&D funding pools, could hold the key to future success in the biotechnology field. Can you begin by introducing…

Canada Michael Rudnicki, chair of the Regenerative Medicine Alliance of Canada (RMAC) discusses the mandate of the newly established organization, the exciting potential of regenerative medicine, and Canada’s competitive edge in this cutting-edge field. Michael, could you share the mandate and mission of the newly established Regenerative Medicine Alliance of Canada…

Serbia Sanja Ivanic, director general of the French-Serbian Chamber of Commerce, discusses the advantages of working in Serbia, the opportunities that the country offers, Serbia’s entrance into the EU, the Chamber’s innovative work strategies, and new and exciting projects across the Balkans. Why should foreign companies come to Serbia? “When looking…

Lithuania Darius Sinkevičius, chairman of the board at the Lithuanian Association of Generic Pharmaceuticals Manufacturers (VGA), explains the main trends impacting the generic pharmaceutical industry in the country as well as the role of off-patent medicines in creating savings for the Lithuanian healthcare system. Can you give to our international audience…

Serbia Vera Nikolic-Dimic, executive director of the American Chamber of Commerce (AmCham) in Serbia, pinpoints the key facets of the Serbian economy that have captivated the interests of American businesses, the challenges and opportunities companies operating in the country are currently facing, as well as the Chamber’s fundamental role in promoting…

Brazil Dr. Florentino Cardoso, president of the Brazilian Medical Association, discusses the challenges of navigating Brazil’s healthcare system and reveals his aim to promote the needs of the medical community to ultimately ensure the best patient outcomes. Can you describe your background and introduce yourself to our executive readership? “As for…

Canada Brian Lewis, president and CEO of MEDEC, speaks towards the importance of building a strong medical device ecosystem and the association’s collaboration with industry stakeholders to push advancements in terms of value-based healthcare to not only improve the overall quality of patient care but also to ultimately support the sustainability…

Serbia Bojan Trkulja, managing director of INOVIA, Serbia’s innovative drug manufacturers association, underlines the importance of cooperation not only between his members but also between all the key stakeholders of the Serbian healthcare and life science industry, concluding that the time for investment in Serbia is now and that the country…

Poland Irena Rej, president of the Polish Pharmaceutical Chamber, Farmacja Polska, discusses the trends of the domestic pharmaceutical market and the recent changes to improve the introduction of innovative products. Furthermore, she highlights the strengths of the local OTC industry and the chamber’s role in facilitating active dialogue with key stakeholders…

Brazil Norberto Prestes, director of the Brazilian Pharmochemicals Manufacturers Association (ABIQUIFI), provides insights into the main dynamics that have been shaping Brazil’s pharmaceutical and API sectors over the past few years, while highlighting his main priorities to further strengthen the country’s pharma industry both inside and outside Brazil. What would you…